autologous tumor-infiltrating lymphocytes (Iovance Biotherapeutics)

Autologous tumor-infiltrating lymphocytes (TIL) are a form of personalized cell therapy used primarily in cancer treatment. The process involves surgically removing a patient's own tumor tissue to isolate T cells that have naturally infiltrated the tumor. These T cells are then expanded ex vivo—typically using interleukin-2 (IL-2) and sometimes additional agonists such as anti-CD3 and anti-4-1BB antibodies—to generate billions of cancer-fighting immune cells. After the patient undergoes a preparative regimen of lymphodepleting chemotherapy, the expanded TILs are infused back into the patient, often followed by further IL-2 administration to enhance their activity. The goal is for these reinfused autologous T cells to recognize and attack residual or metastatic cancer throughout the body. This approach has demonstrated efficacy in advanced melanoma and is under investigation for other solid tumors including non-small cell lung cancer, cervical cancer, gastrointestinal cancers, ovarian cancer, pancreatic ductal adenocarcinoma, colorectal carcinoma, and hepatocellular carcinoma[1][3][4][5][6][7][8].

Other names

TIL therapytumor-infiltrating lymphocyte therapyadoptive cell therapy with TILs